Navigation Links
Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
Date:11/7/2012

VALENCIA, Calif., Nov. 7, 2012 /PRNewswire/ -- Sanguine BioSciences, Inc., a biotechnology company providing transparency to patients in biomedical research, has named Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to its Clinical Advisory Board and Ethics Committee. Ms. Rosario's extensive experience in clinical development and human ethics in clinical trials qualifies her to be the first to join Sanguine's Clinical Advisory Board and Ethics Committee.

Prior to joining Biothera, Inc., Ms. Rosario held several senior positions with MannKind Corporation, serving as Vice President of the Oncology Research Program and as the World Wide Regulatory Affairs Liaison for Oncology. Throughout her career, she has held leadership positions at Chiron Corporation (acquired by Novartis), Aradigm Corporation, Dura Pharmaceuticals, Inc. (acquired by Elan Pharmaceuticals) and Glaxo Wellcome Inc.  At these posts, Ms. Rosario was largely involved with the submission of multiple INDs, NDAs, MAAs in numerous indications, including oncology, immunotherapy and pulmonary.

"I am excited to work with the young, motivated entrepreneurs at Sanguine with the vision of bridging a gap between patients and researchers by collecting biospecimens, characterizing them and making these data available to researchers in an effort to expedite the discovery and availability of new treatments in cancer, among other diseases. I have enjoyed my involvement so far in providing guidance on relevant regulatory topics to ensure compliance with regulatory standards, patient safety, and general advice and direction on activities to move Sanguine forward in their goals and objectives." – Darlene Rosario, B.S., RAC, Vice President of Regulatory Affairs & Quality, Biothera.

"We are excited to have Ms. Rosario advise us on our Regulatory Affairs and Ethical Compliance efforts. Her experiences to date and her personal passions are a unique fit for the company's main commitments: the first of which, is to our patients – to be 100% certain that their data and identities are protected at all times, and that the entire research process is completely transparent; the second is to our researchers – to guarantee consistent and high quality patient biospecimen and associated medical data. She has been an asset to the Company by clearly identifying points requiring regulatory and ethical attention, including strategies and operations in Patient Engagement, Laboratory QA/QC, and Data collection and integrity." – Chief Operations Officer, David Winternheimer, PhD, MBS.

About Sanguine

Sanguine BioSciences is a biotechnology company bridging the gap between patients and researchers developing personalized medicine. The company engages patients in biomedical research by delivering transparency throughout the research process. Sanguine collects and de-identifies patient-derived data in the form of biospecimen, and physician and self-reported information. These data are generated and then made available to researchers involved in drug and biomarker research and discovery. (http://sanguinebio.com)


'/>"/>
SOURCE Sanguine BioSciences, Inc.; INVENT Ventures, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Arecor Appoints Dr. Sarah Howell as Chief Operating Officer
2. Elsevier / MEDai Appoints Tom Zajac as New President
3. Immune Design Corp. Appoints Wayne R. Gombotz, Ph.D. as Chief Development Officer
4. Hybrid Fuels, Inc. Appoints Industry Expert as New CEO
5. BioStorage Technologies Appoints New Member to Board of Directors
6. Selexis SA Appoints Yemi Onakunle as Vice President of Strategic and Market Development
7. Oxford BioTherapeutics Appoints C. Glenn Begley as a Senior Clinical Advisor and Non-executive Director
8. PuraMed BioScience, Inc. Appoints Sue A. Baacke, CPA, as CFO
9. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
10. MAP Pharmaceuticals Appoints W. James OShea to Board of Directors
11. Veracyte Appoints Mark Spring as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... Red Nucleus, a leading ... today announced the opening of a new office in Tokyo, Japan. The new ... Red Nucleus announced the new office in response to customer requests for regional ...
(Date:2/11/2020)... ... February 11, 2020 , ... Synagro Technologies, Inc. , ... announced that the City of Fort Worth has partnered with Synagro of Texas-CDR ... April of 2020, Synagro will assume operation of the city’s current biosolids management ...
(Date:2/5/2020)... ... 05, 2020 , ... Rare Disease Day® , held the last day ... Rare Disorders (NORD), to raise awareness amongst the general public and decision-makers about rare ... “Behind The Mystery” rare disease series will be shining the light on ...
(Date:1/28/2020)... WORTH, Texas (PRWEB) , ... January 28, 2020 ... ... Scientific to be the exclusive distributor to food and beverage manufactures within ... and are considered critical suppliers. This agreement will allow each company to pool ...
Breaking Biology Technology:
(Date:2/13/2020)... LOS ANGELES (PRWEB) , ... February 13, 2020 ... ... publication of its 2020 Global Assessment Report: The Laboratory Analytical & Life Science ... widely considered to be the gold standard of market intelligence for the $70 ...
(Date:2/13/2020)... ... February 13, 2020 , ... Worldwide Business with ... CEO Yoram Ashery to discuss how their revolutionary technology can kill bacteria ... to keep people healthy with their revolutionary nanoparticle technology. Nobio is on the ...
(Date:2/11/2020)... Pa. (PRWEB) , ... February ... ... organization dedicated to solving complex problems for life sciences companies and government ... over 30 years of management consulting expertise to Tunnell, with significant experience ...
Breaking Biology News(10 mins):